Versant-backed Cimeio Gets $50M for Shielded Stem Cell Therapies

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Red Tree Debuts With $272M, Zeroing In On West Coast Startups
Versant, OrbiMed Invest $50M in Startup Inserting Genes in the Liver
Versant, RA Bet $47M on LENZ Therapeutics to Restore Near Vision in Middle Age
Stablix, Seeking to Stabilize Instead of Degrade Proteins, Raises $63M